Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma

Samsung Medical Center

Status: Completed

Conditions: Hepatocellular Carcinoma; Renal Cell Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT01482520

2008-06-050

Details and patient eligibility

About

All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.

No additional treatment or intervention will be conducted except for blood sampling that will be limited to one time only.

Blood samples (10 cc in volume) will be collected from all study participants once they provided written informed consent form. DNA will be extracted from peripheral blood samples using DNA isolation kit.

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study

Trial design

200 participants in 2 patient groups

Renal cell carcinoma

Hepatocellular carcinoma patients